Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects
Authors:
- 18 July 2019
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 39 (10) , 967-978
Abstract
Background Non-clinical study data suggest that DS-8500a, a G protein-coupled receptor 119 agonist, exhibits antidiabetic activity, inhibition of some transporters and induction of cytochrome P450 (CYP) 3A. Statins are substrates for some transporters and CYP3A that may be coadministered with DS-8500a in clinical practice. Objective To determine the potential effects of DS-8500a on the pharmacokinetics of statins, we evaluated the effects of repeated oral administration of DS-8500a 75 mg on the pharmacokinetics of rosuvastatin and atorvastatin in healthy adults. Methods We performed two single-center, open-label, single-sequence studies. In Study I, subjects received single-dose rosuvastatin 10 mg (Period A) and DS-8500a 75 mg once daily + single-dose rosuvastatin 10 mg (Period B). In Study II, subjects received single-dose atorvastatin 10 mg (Period A) and DS-8500a 75 mg once daily + single-dose atorvastatin 10 mg (Period B). Primary pharmacokinetic endpoints were maximum plasma concentration (Cmax) and area under the plasma concentration–time curve (AUC) of rosuvastatin and atorvastatin. Safety was evaluated. Results In Study I, the Cmax and AUC of rosuvastatin increased by 66% and 33%, respectively, when coadministered with DS-8500a, versus rosuvastatin alone. In Study II, the Cmax of atorvastatin increased by 28%, but AUC remained unchanged following coadministration with DS-8500a, versus atorvastatin alone. Treatment-emergent adverse events were mild to moderate and mostly unrelated to the study drugs. Conclusions Multiple doses of DS-8500a increased exposure to rosuvastatin and atorvastatin. This short-term study suggests that the impact of DS-8500a coadministration on atorvastatin exposure is limited and may not be clinically relevant. Nevertheless, caution may be necessary when patients are coadministered rosuvastatin with DS-8500a. ClinicalTrials.gov identifier NCT03699774. Japan Pharmaceutical Information Center identifier JapicCTI-152878.Keywords
Funding Information
- Daiichi Sankyo Co., Ltd
This publication has 28 references indexed in Scilit:
- Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian SubjectsClinical Drug Investigation, 2013
- Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteersEuropean Journal of Clinical Pharmacology, 2012
- Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug InteractionsJournal of Medicinal Chemistry, 2012
- The Role of OATP1B1 and BCRP in Pharmacokinetics and DDI of Novel StatinsCardiovascular Therapeutics, 2011
- Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38The Journal of Clinical Pharmacology, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide ReleaseEndocrinology, 2008
- Corrigendum to “Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor” [Biochem. Biophys. Res. Commun. 326 (2005) 744–751]Biochemical and Biophysical Research Communications, 2005
- Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptorBiochemical and Biophysical Research Communications, 2005
- Clinical Pharmacokinetics of AtorvastatinClinical Pharmacokinetics, 2003